Today, the United States Senate Health, Education, Labor, and Pensions Committee (HELP) released a discussion draft of its legislation to reauthorize FDA user fees for drugs, biologics, and medical devices package, which includes the controversial and divisive Durbin-Braun premarket approval concept and more that would be damaging to the industry. Read more.
![](https://www.yvfh.org/wp-content/themes/dynamik-gen/images/content-filler.png)